Association of<i>JAK2</i>Mutation Status and Cytogenetic Abnormalities at Diagnosis in Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms

Lurdes Zamora(Universitat Autònoma de Barcelona), Fuensanta Millá, Siliva Marcé(Fundación Josep Carreras Contra la Leucemia), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Marisol Xandri(Fundación Josep Carreras Contra la Leucemia), Olga García(Institut Català d'Oncologia), Isabel Granada(Josep Carreras Leukaemia Research Institute)
American Journal of Clinical Pathology
March 19, 2012
10.1309/ajcp74tsvuhhajfx
Cited by 2

Related Papers

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
|Blood|2010|233
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
|Haematologica|2011|215
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
|Blood|2013|189
Human immunodeficiency virus‐associated plasmablastic lymphoma
|Cancer|2012|178